Loading...

FDMT 4D MOLECULAR THERAPEUTICS INC Company Mergers 8-K Filing

4D M

FDMT

4D MOLECULAR THERAPEUTICS INC

(FDMT)

2025 8-K

Q1 Financial Results

Management Change

Financial Results Report

Equity Exchange

Management Changes

Protocol Amendments

New CFO Appointment

Financial Results Report

Stock Offering Announcement

Clinical Trial Results

New Agreement Sealed

Management Changes

Financial Statements

Financial Results

Clinical Trial Update

Pipeline Update

Equity Exchange

Q3 Financial Results

Clinical Trial Update

Financial Results Announcement

Clinical Trial Data Present...

Clinical Trial Results

Sales Agreement

Annual Meeting of Stockholders

Financial Results

Financial Results Announcement

Underwriting Agreement

Appointment and Resignation

Amended and Restated Bylaws

Financial Results

Retirement and Appointment

Financial Results

Financial Results

Underwriting Agreement

Financial Results Announcement

Program Updates

Product Pipeline Updates

External Links:

On October 31, 2025, 4D Molecular Therapeutics, Inc. entered a collaboration with Otsuka Pharmaceutical for exclusive rights to develop its treatment 4D-150 in Asia-Pacific, receiving $85 million upfront and up to $335.5 million in milestones.

AI Assistant

4D MOLECULAR THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.